Pipeline

Our goal is to reimagine nuclear medicine. We are an innovative medicines company developing a pipeline of targeted radioligand therapies and precision imaging radioligands for oncology.

AAA’s approach involves the combination of therapeutics and imaging diagnostics, which we call our oncology theragnostic platform. The idea is to develop complementary drug pairings targeting the same marker or receptor expressed on the tumor that may be used to both image and treat disease.

Different kinds of radioisotopes are used for precision imaging and targeted therapy, depending on the type of energy they release. Some radioisotopes release gamma rays, such as fluorine 18 (F-18) or gallium 68 (Ga-68), which can be useful for imaging of disease to help determine extend and location of the disease. Other radioisotopes, such as lutetium 177 (Lu-177) or actinium 225 (Ac-225) release beta particles or alpha particles, which can damage targeted cells with a therapeutic effect. Our pipeline of investigational drugs includes several different radioisotopes.

Investigational Candidates in Clinical Development:

Disease
Preclinical
Phase I
Phase II
Phase III
Prostate cancer (target PSMA)
Phase III
177Lu-PSMA-617
Targeted Radioligand Therapy
Prostate cancer (target PSMA)
Phase I
225Ac-PSMA-617
Targeted Radioligand Therapy
Prostate cancer (target PSMA)
Phase I
177Lu-PSMA-R2
Targeted Radioligand Therapy
Prostate cancer (target PSMA)
Phase I
68Ga-PSMA-R2
Precision Radioligand Imaging
Prostate cancer (target PSMA)
Phase I
18F-CTT1057
Precision Radioligand Imaging
Multiple Solid Tumors (target GRPR)
Phase I
177Lu-NeoB
Targeted Radioligand Therapy
Multiple Solid Tumors (target GRPR)
Phase II
68Ga-NeoB
Precision Radioligand Imaging
Glioblastoma, others (target Integrin alphavbeta3/5)
Preclinical
177Lu-FF-10158
Targeted Radioligand Therapy
Glioblastoma, others (target Integrin alphavbeta3/5)
Phase I
68Ga-FF-10158
Precision Radioligand Imaging